Your browser doesn't support javascript.
loading
[Consistency of ALK Ventana-D5F3 immunohistochemistry interpretation in lung adenocarcinoma among Chinese histopathologists].
Li, L; Zhang, L P; Han, Y C; Wang, W Y; Jin, Y; Xia, Q X; Liu, Y P; Xiang, J; Liu, C; Lu, S S; Wu, W; Chen, Z; Pang, J; Xi, Y F; Zheng, Y S; Gu, D M; Fan, J; Chang, X N; Wang, W W; Wang, L; Zhang, Z H; Yan, X C; Sun, Y; Li, J; Hou, F; Zhang, J Y; Huang, R F; Lu, J P; Wang, Z; Hu, Y B; Yuan, H T; Dong, Y J; Wang, L; Ke, Z Y; Geng, J S; Guo, L; Zhang, J; Ying, J M.
Afiliação
  • Li L; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Zhang LP; Department of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
  • Han YC; Department of Pathology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China.
  • Wang WY; Department of Pathology, West China Hospital of Sichuan University, Chengdu 610041, China.
  • Jin Y; Department of Pathology, Fudan University Cancer Center; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai 200032, China.
  • Xia QX; Department of Molecular Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
  • Liu YP; Department of Pathology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
  • Xiang J; Department of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Liu C; Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
  • Lu SS; Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
  • Wu W; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Chen Z; Department of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
  • Pang J; Department of Pathology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China.
  • Xi YF; Department of Pathology, West China Hospital of Sichuan University, Chengdu 610041, China.
  • Zheng YS; Department of Pathology, Fudan University Cancer Center; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai 200032, China.
  • Gu DM; Department of Pathology, Fudan University Cancer Center; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai 200032, China.
  • Fan J; Department of Molecular Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
  • Chang XN; Department of Molecular Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
  • Wang WW; Department of Pathology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
  • Wang L; Department of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Zhang ZH; Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
  • Yan XC; Institute of Pathology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China.
  • Sun Y; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Li J; Department of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
  • Hou F; Department of Pathology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China.
  • Zhang JY; Department of Pathology, West China Hospital of Sichuan University, Chengdu 610041, China.
  • Huang RF; Department of Pathology, Fudan University Cancer Center; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai 200032, China.
  • Lu JP; Department of Pathology, Fudan University Cancer Center; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai 200032, China.
  • Wang Z; Department of Molecular Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
  • Hu YB; Department of Pathology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
  • Yuan HT; Department of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Dong YJ; Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
  • Wang L; Department of Pathology, Xijing Hospital, Air Force Military Medical University, Xi'an 710032, China.
  • Ke ZY; Department of Pathology, Xijing Hospital, Air Force Military Medical University, Xi'an 710032, China.
  • Geng JS; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Guo L; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Zhang J; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Ying JM; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Bing Li Xue Za Zhi ; 48(12): 921-927, 2019 Dec 08.
Article em Zh | MEDLINE | ID: mdl-31818064
ABSTRACT

Objective:

To understand the consistency of ALK Ventana-D5F3 immunohistochemistry (IHC) interpretation in Chinese lung adenocarcinoma among histopathologists from different hospitals, and to recommend solution for the problems found during the interpretation of ALK IHC in real world, with the aim of the precise selection of patients who can benefit from ALK targeted therapy.

Methods:

This was a multicenter and retrospective study. A total of 109 lung adenocarcinoma cases with ALK Ventana-D5F3 IHC staining were collected from 31 lung cancer centers in RATICAL research group from January to June in 2018. All cases were scanned into digital imaging with Ventana iSCANcoreo Digital Slide Scanning System and scored by 31 histopathologists from different centers according to ALK binary (positive or negative) interpretation based on its manufacturer's protocol. The cases with high inconsistency rate were further analyzed using FISH/RT-PCR/NGS.

Results:

There were 49 ALK positive cases and 60 ALK negative cases, confirmed by re-evaluation by the specialist panel. Two cases (No. 2302 and No.2701) scored as positive by local hospitals were rescored as negative, and were confirmed to be negative by RT-PCR/FISH/NGS. The false interpretation rate of these two cases was 58.1% (18/31) and 48.4% (15/31), respectively. Six out of 31 (19.4%) pathologists got 100% accuracy. The minimum consistency between every two pathologists was 75.8%.At least one pathologist gave negative judgement (false negative) or positive judgement (false positive) in the 49 positive or 60 negative cases, accounted for 26.5% (13/49), 41.7% (25/60), respectively, with at least one uncertainty interpretation accounted for 31.2% (34/109).

Conclusion:

There are certain heterogeneities and misclassifications in the real world interpretation of ALK-D5F3 IHC test, which need to be guided by the oncoming expert consensus based on the real world data.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imuno-Histoquímica / Adenocarcinoma de Pulmão / Quinase do Linfoma Anaplásico / Neoplasias Pulmonares Tipo de estudo: Guideline / Observational_studies Limite: Humans Idioma: Zh Revista: Zhonghua Bing Li Xue Za Zhi Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imuno-Histoquímica / Adenocarcinoma de Pulmão / Quinase do Linfoma Anaplásico / Neoplasias Pulmonares Tipo de estudo: Guideline / Observational_studies Limite: Humans Idioma: Zh Revista: Zhonghua Bing Li Xue Za Zhi Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China